

# CEPI - IABS

## Cross learning experience human and animal vaccine licensure based on technology platforms

Palais de l'Académie Royale des Sciences  
Rue Ducale, 1  
B 1000 Bruxelles

### **Mark Van Ooij, Ph.D.**

Scientific Director  
Janssen Vaccines  
Newtonweg 1  
2333CP Leiden  
The Netherlands  
Tel: +31654281938  
Fax: +31715199800  
e-mail: mvanooi@its.jnj.com



- I performed my PhD studies at the University in Nijmegen, the Netherlands, within the Virology department. During my PhD I worked on picornaviruses to study the presence of RNA elements essential for virus replication. Obtained PhD degree in 2007.
- In 2005 I started working at Crucell (Currently Janssen Vaccines) at the Molecular Virology department and worked on the introduction of molecular biological techniques as release tests. I expanded my scope in the following year to cell based methods and biochemical methods with focus on content, potency and purity methods for vaccines.
- Responsibilities were expanded to contamination testing, and risk management, focusing on TSE/BSE, virus safety and extraneous agents related analytical detection techniques and involved in setting up analytical strategies for release and stability testing of recombinant viral vaccines. Assumed content responsibility of the PER.C6 cell line management with licensees.
- As of 2016 USP Viral Vaccine expert panel member.
- Within the VPAD organisation moved from Analytical Development to Drug Substance Development in 2018 and became "Head of Platform Innovation and Implementation" to prepare strategic topics for discussion with Health Agencies Scientific Advice meetings. Focus is on PER.C6 management, Advac/ PER.C6 platform management and OMCL/ National Control Lab management for Janssens Vaccine Lot release.